Form 4: HilleVax Director Patrick Heron Receives Equity Grant, Bolstering Stake

HilleVax, Inc. Director Patrick J. Heron was granted 17,199 Restricted Stock Units as part of the company's non-employee director compensation program, further aligning his interests with shareholders.

Summary

• Patrick J. Heron, a Director of HilleVax, Inc. (HLVX), was granted 17,199 Restricted Stock Units (RSUs) on June 23, 2025.
• These RSUs were granted under the Registrant's Non-Employee Director Compensation Program.
• The RSUs have a grant price of $0.00.
• 100% of the RSUs will vest on the first anniversary of the grant date or upon a Change in Control, whichever occurs first, provided Mr. Heron continues his service on the board.
• Mr. Heron also indirectly beneficially owns 8,535,337 shares of Common Stock through Frazier Life Sciences X, L.P., where he shares voting and investment power.

Sentiment

Score: 6

Explanation: The document reports a routine equity compensation grant to a director, which is a neutral to slightly positive event as it aligns the director's interests with shareholders. There are no negative financial implications or significant new risks disclosed.

Positives

• The grant of Restricted Stock Units (RSUs) to Director Patrick J. Heron aligns his financial interests with those of HilleVax, Inc. shareholders, promoting long-term value creation.
• The compensation program for non-employee directors, which includes equity grants, is a standard practice that helps attract and retain qualified board members.

Negatives

• No specific negative aspects are disclosed in this Form 4 filing, which primarily reports a routine equity compensation grant.

Risks

• The vesting of the 17,199 Restricted Stock Units is contingent upon Patrick J. Heron's continued service on HilleVax's board of directors through the vesting date.
• The vesting is also subject to a 'Change in Control' as defined in the Registrant's 2022 Incentive Award Plan, which could accelerate vesting but also introduces a dependency on such an event.

Future Outlook

The future outlook indicates that the 17,199 Restricted Stock Units granted to Director Patrick J. Heron are expected to vest on the first anniversary of the grant date (June 23, 2026) or upon a Change in Control, contingent on his continued service on the board. This suggests a continued alignment of the director's interests with the company's long-term performance.

Management Comments

• "The Restricted Stock Units ('RSUs') were granted on June 23, 2025 pursuant to the Registrant's Non-Employee Director Compensation Program."
• "100% of the total number of RSUs granted shall vest on the first to occur of (i) the first anniversary of the date of grant or (ii) a Change in Control (as defined in the Registrant's 2022 Incentive Award Plan), in each case, subject to the non-employee director continuing in service on the Registrant's board of directors through such vesting date."
• "The shares reported herein are held of record by Frazier Life Sciences X, L.P. ('FLS X'). The general partner of FLS X is FHMLS X, L.P., and the general partner of FHMLS X, L.P. is FHMLS X, L.L.C. James Topper, M.D., Ph.D., and Patrick Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."

Industry Context

The grant of Restricted Stock Units (RSUs) to non-employee directors is a common and widely accepted practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies generally. This form of compensation is designed to align the interests of board members with those of shareholders by providing an equity stake that vests over time or upon specific events, encouraging long-term strategic oversight and value creation.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as part of a non-employee director compensation program is a standard practice across publicly traded companies, particularly in the life sciences sector.
• The vesting schedule, which includes a one-year cliff vesting or accelerated vesting upon a change in control, is typical for such grants, similar to compensation structures seen at comparable biotech firms like Moderna (MRNA) or BioNTech (BNTX) for their non-executive directors, though specific numbers and plans vary.
• The disclosure of indirect beneficial ownership through investment funds, where the director holds a managing member role and shares voting power, is also a common structure for directors who are also partners in venture capital or private equity firms, such as those seen with directors from Flagship Pioneering or OrbiMed Advisors on various biotech boards.

Corporate Governance

Related Party Transactions

• Patrick J. Heron indirectly beneficially owns 8,535,337 shares of Common Stock through Frazier Life Sciences X, L.P. ('FLS X'). Mr. Heron is a sole managing member of FHMLS X, L.L.C., which is the general partner of FHMLS X, L.P., which in turn is the general partner of FLS X. He shares voting and investment power over these securities.

Stakeholder Impact

• Shareholders: The equity grant to a director aligns their interests with shareholders, potentially leading to more shareholder-friendly decisions and long-term value creation.

Next Steps

• Vesting of the 17,199 Restricted Stock Units on the first anniversary of the grant date (June 23, 2026) or upon a Change in Control, subject to continued service.

Key Dates

Keywords

HilleVax, HLVX, SEC Form 4, insider transaction, Restricted Stock Units, RSU, director compensation, beneficial ownership, equity grant, corporate governance